US FDA approves Abbott’s FreeStyle Libre 3 system for diabetic patients was reported by MedicalDevice-Network.com, 1 June 2022.
The US Food and Drug Administration (FDA) has granted clearance to Abbott’s next-generation FreeStyle Libre 3 system for use by diabetic patients aged four years and above.
The new device, which includes a continuous glucose monitoring (CGM) sensor, recorded a 7.9% overall mean absolute relative difference (MARD) and is claimed to be the most accurate 14-day CGM system. FreeStyle Libre 3 sends glucose readings directly from the glucose sensor, which is said to be the smallest and thinnest in the world, to a smartphone every minute. The CGM system also has strong Bluetooth integration, with a range of up to 33ft, which represents a 50% increase over other CGMs.